Penumbra (PEN)
(Delayed Data from NYSE)
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Zacks News
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
Illumina (ILMN) Progresses in Pathogen Genomic Technologies
by Zacks Equity Research
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo
by Zacks Equity Research
Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays
by Zacks Equity Research
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
Here's Why Investors Should Retain Henry Schein (HSIC) for Now
by Zacks Equity Research
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
by Zacks Equity Research
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays
by Zacks Equity Research
Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.
Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?
by Zacks Equity Research
Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.
Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.
Zacks.com featured highlights include Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk
by Zacks Equity Research
Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk are part of the Zacks Screen of the Week article.
Buy These 4 Low-Beta Stocks to Endure Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.
Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.
Penumbra (PEN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 109.09% and 4.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG
Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.
Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Should You Buy Penumbra (PEN) Ahead of Earnings?
by Zacks Equity Research
Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Stock Picks for Week of February 13, 2023
by Panel Of Zacks Experts
A Medical and Financial Stock Worth a Look.